Research
Hormonal
GLP-1 medicines reduce food intake, body weight, insulin resistance and inflammation.
GLP-1 medicines can be considered for managing weight and metabolic health in patients with type 2 diabetes and obesity.
StrongSupportsmedium confidence
Glucagon-like peptide-1 (GLP-1) medicines reduce food intake, body weight, insulin resistance and inflammation.
Why this rating
The claim is based on data summarized from trials and registries.
Source
Glucagon-like peptide-1 medicines and cancer
Julian M. Yabut et al. · Nature Cancer · 2026
DOI 10.1038/s43018-025-01110-1
otherCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →